Milestone Pharmaceuticals (MIST): Assessing the Path to the $6.30 Analyst Target
Key Takeaways
- The central target of $6.30 is the arithmetic mean of six verified analyst price targets on Milestone Pharmaceuticals (MIST), a Nasdaq-listed biopharmaceutical company.
- With the stock trading near $0.65, reaching $6.30 would require a gain of roughly 870%, a very large move by any standard.
- Individual targets range widely from $3.00 (Cantor Fitzgerald) to $8.00 (H.C. Wainwright and TD Cowen), reflecting deep disagreement about the commercial launch and pipeline.
- The strongest support is CARDAMYST payer coverage above 50% and the larger atrial fibrillation with rapid ventricular rate (AFib-RVR) opportunity.
- The biggest risks are a slow CARDAMYST launch, rising losses, dilution, and reliance on uncertain regulatory and clinical outcomes.
- For more context on this company, explore the Major News, Today's Price Move, Forecast, and Earnings pages.
- To see how automated systems are trading this and other names, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Milestone Pharmaceuticals Inc. is a Montreal-based biopharmaceutical company focused on cardiovascular medicines. Its lead product, CARDAMYST (etripamil) nasal spray, is FDA-approved to convert episodes of paroxysmal supraventricular tachycardia (PSVT) to normal rhythm in adults, and it was commercially launched in February 2026.
Reviewing six individually attributed, current price targets yields a range of $3.00 to $8.00 and an arithmetic mean of $6.33, which rounds to a $6.30 central target. H.C. Wainwright and TD Cowen carry $8.00 targets; Wells Fargo and Piper Sandler sit at $7.00; Raymond James lowered its target to $5.00 from $6.00 in October 2026; and Cantor Fitzgerald initiated coverage with a $3.00 target. Despite the spread, every rating is a Buy, Overweight, or Strong Buy equivalent.
The dispersion matters more than the average. Cantor's cautious number still frames CARDAMYST peak sales of roughly $250 million to $300 million and argues investors are pricing in almost no value for the ongoing Phase 3 AFib-RVR program. Raymond James, by contrast, trimmed its target on slower-than-expected launch execution, noting that better payer coverage and prescriber breadth must still convert into revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
As of late October 2026, MIST traded near $0.65, down roughly 65% year-to-date and within reach of its 52-week low of about $0.63, versus a 52-week high of $3.06. The company's market capitalization was approximately $87 million, with about $170 million in cash on the balance sheet.
Because the stock is under $1, reaching the $6.30 central target implies a move of roughly 870% — an extreme re-rating rather than a modest or substantial gain. Such a path would require not only accelerating CARDAMYST revenue but also a credible de-risking of the AFib-RVR pipeline, which analysts describe as the far larger opportunity.
What Could Support a Move Toward the Target
The commercial thesis rests on CARDAMYST's unique positioning as a self-administered, at-home treatment for acute PSVT episodes, a condition patients historically managed in emergency settings. Management reported that commercial payer coverage surpassed 50% of U.S. covered lives, with more than 600 independent prescribers and over 1,200 prescriptions written in the second quarter. If prescription conversion improves and reliance on copay assistance declines, gross-to-net economics could strengthen.
The pipeline is the central bull case. The Phase 3 program evaluating etripamil in AFib-RVR addresses a substantially larger patient population, and Cantor Fitzgerald argues this indication is being largely ignored at current share levels. A positive data readout would materially reshape the valuation debate. From what I see, this remains a key area to monitor closely.
What Could Prevent the Target From Being Reached
The principal obstacle is execution. Second-quarter revenue was approximately $0.56 million, below expectations, while the net loss widened to about $28.6 million as selling, general, and administrative costs rose. Monetization has been weak, with many prescriptions flowing through copay assistance and average net revenue per prescription expected to remain low through 2026.
Funding risk is also material. The share count has risen sharply as the company has raised capital, and continued cash burn could bring further dilution. Short interest stood around 15% of the float, reflecting skepticism about the launch. Regulatory outcomes outside the United States and payer controls add further uncertainty.
Technical Levels and Market Structure
MIST sits at the bottom of a prolonged downtrend, near its 52-week low in the $0.63 to $0.70 zone. The 50-day moving average, near $0.93, and the 200-day moving average, near $1.41, now represent overhead supply rather than support. A durable recovery would first need to reclaim the roughly $0.80 to $0.93 area, where the stock consolidated before its October slide, before any discussion of the multi-dollar target zone becomes realistic.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of about 12 months, though individual firms rarely state it explicitly for early-stage biotechs. The most important near-term catalysts are the next quarterly results, expected in November 2026, updates on CARDAMYST prescription trends and payer coverage, progress on the European marketing application, and any AFib-RVR Phase 3 developments. Target revisions, particularly downward, have been a recurring theme and warrant close attention.
Using AI Daily Buy/Sell Signals in Practice
Tickeron's AI Daily Buy/Sell Signals have become a regular part of my routine for names like this. The system continuously monitors thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like MIST, these signals can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual chart review alone. Traders seeking a systematic complement to fundamental research may find the signals a useful tool for staying ahead of rapidly changing conditions.
Final Assessment
The $6.30 central target is the arithmetic mean of six verified analyst price targets spanning $3.00 to $8.00, and it sits roughly 870% above the current price near $0.65 — a reflection of how far the shares have fallen rather than a consensus that the stock will soon recover. The bull case centers on CARDAMYST's launch trajectory and the AFib-RVR pipeline, while the bear case rests on weak early monetization, rising losses, and dilution. Analyst targets differ sharply precisely because these two narratives point in opposite directions. Reaching $6.30 would require a fundamental commercial inflection plus successful pipeline de-risking, and no outcome is guaranteed.
Exploring Tickeron AI Tools for Deeper Analysis
In my own research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to cross-check technical setups and market sentiment on volatile names. It provides a structured way to track signals across thousands of securities, which complements the fundamental work on launch metrics and pipeline updates. The platform has helped me stay organized when reviewing multiple catalysts at once.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MIST in upward trend: price may jump up because it broke its lower Bollinger Band on October 23, 2026
MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 37 cases where MIST's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for MIST's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for MIST just turned positive on October 12, 2026. Looking at past instances where MIST's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
Following a +3.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIST as a result. In 74 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MIST entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.430) is normal, around the industry mean (3.035). P/E Ratio (-0.997) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. MIST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of cardiovascular medicines
Industry Biotechnology
Advertisement